Joanne van Ryn

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

Charles V. Pollack, Paul Reilly, Joanne van Ryn et al. · New England Journal of Medicine · 2017 · 1.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A specific antidote for dabigatran: functional and structural characterization

Felix Schiele, Joanne van Ryn, Keith A. Canada et al. · Blood · 2013 · 561 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran

Wei Zhou, Sönke Schwarting, Sergio Illanes et al. · Stroke · 2011 · 326 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial

Stephan Glund, Joachim Stangier, Michael Schmohl et al. · The Lancet · 2015 · 318 citations

Medicine, Pharmacology, Pharmacotherapy +10

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran

Viktoria Moschetti, Stephen H. Norris, Joachim Stangier et al. · Thrombosis and Haemostasis · 2015 · 245 citations

Pharmacy, Pharmacokinetics, Pharmacology +8